Showing results (1501-1510 of 1,524) with videos related to
Sort By:
Pageof 153
The New England Journal of Medicine|March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerRonan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.Nature Communications|October 6, 2025
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancerMing Lei, Michael J Overman, Jin Yao, et al.Nature Communications|November 28, 2023
Dbh+ catecholaminergic cardiomyocytes contribute to the structure and function of the cardiac conduction system in murine heartTianyi Sun, Alexander Grassam-Rowe, Zhaoli Pu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 TrialYelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.The Lancet Regional Health. Western Pacific|September 8, 2025
Immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trialGuo-Hua Zhong, Zhao-Feng Bi, Kai Chu, et al.Science Advances|April 1, 2026
Tissue-specific inflammation induces cell state plasticity with oncogenic addiction in mucosal melanomaXuhui Ma, Yanni Ma, Li Zhang, et al.Biomaterials|May 14, 2015
Phytomolecule icaritin incorporated PLGA/TCP scaffold for steroid-associated osteonecrosis: Proof-of-concept for prevention of hip joint collapse in bipedal emus and mechanistic study in quadrupedal rabbitsLing Qin, Dong Yao, Lizhen Zheng, et al.Future Oncology (London, England)|March 15, 2023
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagusYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.Nature|March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancerKohei Shitara, Jaffer A Ajani, Markus Moehler, et al.Pageof 153